• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Axsome Therapeutics (AXSM)

Common Shares
Sell: $111.20|Buy: $115.00|Change: 2.38 (2.17%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Address

200 Broadway
3rd Floor
New York
NY
USA
10038

Telephone

+1 212 3323241

Website

https://www.axsome.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Axsome Therapeutics Inc Fourth Quarter Earnings Conference Call for 20252026-02-18T08:00:00
Axsome Therapeutics Inc Fourth Quarter Earnings Results for 20252026-02-18T00:00:00
Axsome Therapeutics Inc Annual Report for 20252026-02-18T00:00:00
Axsome Therapeutics Inc Third Quarter Earnings Conference Call for 20252025-11-12T08:00:00
Axsome Therapeutics Inc Third Quarter Earnings Results for 20252025-11-12T00:00:00
Axsome Therapeutics Inc Second Quarter Earnings Conference Call for 20252025-08-05T08:00:00
Axsome Therapeutics Inc Second Quarter Earnings Results for 20252025-08-05T00:00:00
Axsome Therapeutics Inc Annual General Meeting for 20252025-06-06T09:00:00
Axsome Therapeutics Inc First Quarter Earnings Conference Call for 20252025-05-05T08:00:00
Axsome Therapeutics Inc First Quarter Earnings Result for 20252025-05-05T00:00:00

Previous key dates

NameKey Date
Leerink Partners Global Biopharma Conference2025-03-12T10:40:00
TD Cowen 45th Annual Health Care Conference2025-03-04T09:50:00
Axsome Therapeutics Inc Fourth Quarter Earnings Conference Call for 20242025-02-18T08:00:00
Axsome Therapeutics Inc Fourth Quarter Earnings Result for 20242025-02-18T00:00:00
Axsome Therapeutics Inc Annual Report for 20242025-02-18T00:00:00
SYMBRAVO FDA Approval Call2025-01-31T08:00:00
AXS-05 in Alzheimer’s Disease Agitation Phase 3 Topline Results2024-12-30T08:00:00
Axsome Therapeutics Inc Third Quarter Earnings Conference Call for 20242024-11-12T08:00:00
Axsome Therapeutics Inc Third Quarter Earnings Result for 20242024-11-12T00:00:00
Axsome Therapeutics will participate at 2024 Cantor Global Healthcare Conference2024-09-18T09:45:00
Axsome Therapeutics will participate at Baird 2024 Global Healthcare Conference2024-09-11T08:30:00
Axsome Therapeutics will participate at 2024 Wells Fargo Healthcare Conference2024-09-05T00:00:00
Axsome Therapeutics will participate at Morgan Stanley 22nd Annual Global Healthcare Conference2024-09-04T16:50:00
Axsome Therapeutics Inc Second Quarter Earnings Conference Call for 20242024-08-05T08:00:00
Axsome Therapeutics Inc Second Quarter Earnings Result for 20242024-08-05T00:00:00
Goldman Sachs 45th Annual Global Healthcare Conference2024-06-12T00:00:00
Axsome Therapeutics Inc Annual General Meeting for 20242024-06-07T09:00:00
William Blair 44th Annual Growth Stock Conference2024-06-05T14:00:00
Axsome Therapeutics to Participate in Bank of America 2024 Healthcare Conference2024-05-16T08:00:00
Axsome Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference2024-05-14T13:35:00
Axsome Therapeutics Inc First Quarter Earnings Conference Call for 20242024-05-06T08:00:00
Axsome Therapeutics Inc First Quarter Earnings Result for 20242024-05-06T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.